| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total revenue | 11,790 | 11,175 | 24,124 | |
| Cost of goods sold | 0 | 0 | 4,435 | |
| Research and development (including 421 and 0 for the three months ended september 30, 2025 and 2024, respectively, from a related party and 1,242 and 0 for the nine months ended september 30, 2025 and 2024, respectively, from a related party) | 27,252 | 29,886 | 35,031 | |
| General and administrative | 16,070 | 17,072 | 18,957 | |
| Restructuring and impairment | 140 | 447 | 46 | |
| Total operating costs and expenses | 43,462 | 47,405 | 58,469 | |
| Loss from operations | -31,672 | -36,230 | -34,345 | |
| Non-cash interest expense on liabilities related to the sales of future royalties | 6,047 | 5,394 | 6,020 | |
| Interest income | 2,819 | 1,969 | 3,437 | |
| Other income (expense), net (including income of 190 and 0 for the three months ended september 30, 2025 and 2024, respectively, from a related party and income of 1,051 and 0 for the nine months ended september 30, 2025 and 2024, respectively, from a related party) | -121 | 260 | -120 | |
| Total non-operating income (expense), net | -3,349 | -3,165 | -2,703 | |
| Loss before provision for income taxes | - | - | -37,048 | |
| Loss before provision (benefit) for income taxes and equity method investment | -35,021 | -39,395 | - | |
| Provision (benefit) for income taxes | -33 | -188 | 9 | |
| Loss before equity method investment | -34,988 | -39,207 | - | |
| Loss from equity method investment | -534 | -2,386 | - | |
| Net loss | -35,522 | -41,593 | -37,057 | |
| Earnings per share, basic, total | -1.87 | -2.95 | -0.18 | |
| Earnings per share, diluted, total | -1.87 | -2.95 | -0.18 | |
| Weighted average number of shares outstanding, basic, total | 18,946,559 | 14,087,307 | 209,249,000 | |
| Weighted average number of shares outstanding, diluted, total | 18,946,559 | 14,087,307 | 209,249,000 | |
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)